Amgen (AMGN) Capital Expenditures (2009 - 2026)
Amgen (AMGN) posted quarterly Capital Expenditures of $712.0 million for Q1 2026, up 73.24% year-over-year from $411.0 million in Q1 2025, and up 10.9% quarter-over-quarter from $642.0 million in Q4 2025.
Amgen (AMGN) Capital Expenditures (2009 - 2026) Analysis & Trends
Amgen's Capital Expenditures history runs 18 years deep, the most recent figure standing at $712.0 million for Q1 2026.
- In Q1 2026, Capital Expenditures rose 73.24% year-over-year to $712.0 million; the TTM figure through Mar 2026 stood at $2.2 billion (up 69.07% YoY), while the FY2025 annual figure was $1.9 billion, up 69.53% from the prior year.
- Capital Expenditures for Q1 2026 stood at $712.0 million, up from $642.0 million in the prior quarter.
- The five-year high for Capital Expenditures was $712.0 million in Q1 2026, with the low at $160.0 million in Q3 2022.
- The 5-year median for Capital Expenditures is $271.0 million (2023), against an average of $336.1 million.
- The sharpest annual moves came in 2022 and 2023: Capital Expenditures slumped 33.88% in 2022, then surged 81.05% in 2023.
- Amgen's Capital Expenditures stood at $340.0 million in 2022, then dropped by 26.76% to $249.0 million in 2023, then soared by 49.0% to $371.0 million in 2024, then jumped by 73.05% to $642.0 million in 2025, then gained by 10.9% to $712.0 million in 2026.
- Business Quant data shows AMGN's Capital Expenditures at $712.0 million in Q1 2026, $642.0 million in Q4 2025, and $436.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.73 Bn | 631.97 Bn | 17.26 Bn | 1.32 Bn |
| 2 | AbbVie | 469.89 Bn | 463.32 Bn | 12.70 Bn | 322.00 Mn |
| 3 | Merck | 377.61 Bn | 370.47 Bn | 12.21 Bn | 893.00 Mn |
| 4 | Novartis Ag | 303.24 Bn | 295.55 Bn | 11.24 Bn | 321.00 Mn |
| 5 | Astrazeneca | 257.81 Bn | 252.91 Bn | 12.86 Bn | 1.86 Bn |
| 6 | Amgen | 237.20 Bn | 223.21 Bn | 7.24 Bn | 513.00 Mn |
| 7 | Gilead Sciences | 182.20 Bn | 179.02 Bn | 6.22 Bn | 140.00 Mn |
| 8 | Pfizer | 159.71 Bn | 148.02 Bn | 10.94 Bn | 533.00 Mn |
| 9 | Gsk | 106.41 Bn | 102.24 Bn | 8.24 Bn | -440.07 Mn |
| 10 | Sanofi | 55.04 Bn | 47.66 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 513.00 Mn |
| Jun 30, 2026 | 513.00 Mn |
| Mar 31, 2026 | 712.00 Mn |
| Mar 31, 2026 | 712.00 Mn |
| Dec 31, 2025 | 642.00 Mn |
| Dec 31, 2025 | 642.00 Mn |
| Sep 30, 2025 | 436.00 Mn |
| Sep 30, 2025 | 436.00 Mn |
| Jun 30, 2025 | 369.00 Mn |
| Jun 30, 2025 | 369.00 Mn |
| Mar 31, 2025 | 411.00 Mn |
| Mar 31, 2025 | 411.00 Mn |
| Dec 31, 2024 | 371.00 Mn |
| Dec 31, 2024 | 371.00 Mn |
| Sep 30, 2024 | 257.00 Mn |
| Sep 30, 2024 | 257.00 Mn |
| Jun 30, 2024 | 238.00 Mn |
| Jun 30, 2024 | 238.00 Mn |
| Mar 31, 2024 | 230.00 Mn |
| Mar 31, 2024 | 230.00 Mn |